AnalystsMichael KingMichael King's Stock Forecasts
AnalystsMichael King
Sectors:
Analyst Ranking
Bottom 1%
#4833 out of 4868 analysts
Average Return
-18.24%
Win Rate
34%42 out of 125
Risk vs Reward
Poor
Good
Michael King's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Argenx SeARGX | +376.50% | $21.02 | $100.16 | 2017-06-11 - 2018-06-12 | Buy |
Argenx SeARGX | +290.04% | $23.70 | $92.44 | 2017-11-12 - 2018-11-13 | Buy |
Werewolf Therapeutics IncHOWL | +150.21% | $2.43 | $6.08 | 2023-03-23 - 2024-03-22 | Strong Buy |
Werewolf Therapeutics IncHOWL | +147.47% | $2.97 | $7.35 | 2023-02-26 - 2024-02-26 | Strong Buy |
Werewolf Therapeutics IncHOWL | +100.87% | $3.43 | $6.89 | 2023-02-16 - 2024-02-16 | Strong Buy |
Michael King Analyst Color
Get additional color on Michael King's coverage of popular stocks
Michael King's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Apollomics IncAPLM | 4 | Strong Buy | $650.00 | N/A | Maintains | a year ago |
Sonnet Biotherapeutics Holdings IncSONN | 7 | Strong Buy | $1,179.20 | N/A | Assumes | 2 years ago |
Lantern Pharma IncLTRN | 9 | Strong Buy | $11.00 | N/A | Reiterates | 2 years ago |
Biomea Fusion IncBMEA | 11 | Strong Buy | $32.00 | N/A | Reiterates | 2 years ago |
Jasper Therapeutics IncJSPR | 10 | Strong Buy | $68.50 | N/A | Reiterates | 2 years ago |
Coeptis Therapeutics Holdings IncCOEP | 7 | Strong Buy | $200.00 | N/A | Assumes | 2 years ago |
Werewolf Therapeutics IncHOWL | 6 | Strong Buy | $8.30 | N/A | Assumes | 2 years ago |
Regeneron Pharmaceuticals IncREGN | 11 | Strong Buy | $862.00 | N/A | Reiterates | 2 years ago |
Exelixis IncEXEL | 10 | Strong Buy | $24.00 | N/A | Reiterates | 2 years ago |
Ocean Biomedical IncOCEA | 3 | Strong Buy | $17.00 | N/A | Maintains | 2 years ago |
Agenus IncAGEN | 7 | Strong Buy | $166.00 | N/A | Reiterates | 2 years ago |
Xencor IncXNCR | 5 | Strong Buy | $42.00 | N/A | Reiterates | 2 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $304.00 | N/A | Reiterates | 2 years ago |
Intellia Therapeutics IncNTLA | 6 | Strong Buy | $116.00 | N/A | Maintains | 2 years ago |
Compass Therapeutics IncCMPX | 1 | Strong Buy | $10.30 | N/A | Initiates Coverage On | 2 years ago |
Vincerx Pharma IncVINC | 2 | Buy | $560.00 | N/A | Maintains | 3 years ago |
Scholar Rock Holding CorpSRRK | 1 | Buy | $24.00 | N/A | Initiates Coverage On | 3 years ago |
Salarius Pharmaceuticals IncSLRX | 2 | Buy | $800.00 | N/A | Maintains | 3 years ago |
Anaptysbio IncANAB | 2 | Buy | $46.00 | N/A | Maintains | 3 years ago |
Agios Pharmaceuticals IncAGIO | 6 | Buy | $96.00 | N/A | Maintains | 3 years ago |
Tuhura Biosciences IncHURA | 2 | Buy | $5,250.00 | N/A | Maintains | 3 years ago |
Xilio Therapeutics IncXLO | 1 | Buy | $36.00 | N/A | Initiates Coverage On | 3 years ago |
Elevation Oncology IncELEV | 1 | Buy | $12.00 | N/A | Initiates Coverage On | 3 years ago |
Cogent Biosciences IncCOGT | 2 | Buy | $31.00 | N/A | Maintains | 3 years ago |
Infinity Pharmaceuticals IncINFI | 1 | Buy | $9.00 | N/A | Initiates Coverage On | 4 years ago |
Syros Pharmaceuticals IncSYRS | 1 | Buy | $160.00 | N/A | Maintains | 6 years ago |
Aceragen IncACGN | 2 | Buy | $4.00 | N/A | Maintains | 7 years ago |
Argenx SeARGX | 2 | Buy | $36.00 | N/A | Maintains | 7 years ago |
Deciphera Pharmaceuticals IncDCPH | 1 | Buy | $38.00 | N/A | Initiates Coverage On | 8 years ago |
Loxo Oncology IncLOXO | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.